| A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration (NCT07718165) | Abbisko Therapeutics Co, Ltd | 2026-09-01 |
| A Phase 2 Study of ABSK043 Combined With Osimertinib (NCT07710612) | Abbisko Therapeutics Co, Ltd | 2026-08-31 |
| A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants (NCT07700953) | Abbisko Therapeutics Co, Ltd | 2026-07-21 |
| A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) (NCT07417189) | Abbisko Therapeutics Co, Ltd | 2026-03-02 |
| A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia (NCT07297875) | Abbisko Therapeutics Co, Ltd | 2025-12-10 |
| A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib (NCT07164170) | Abbisko Therapeutics Co, Ltd | 2025-09-22 |
| A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors (NCT07288957) | Abbisko Therapeutics Co, Ltd | 2025-07-22 |
| A Study in Children With Achondroplasia (NCT07301463) | Abbisko Therapeutics Co, Ltd | 2025-06-20 |
| ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression (NCT07327034) | Abbisko Therapeutics Co, Ltd | 2025-06-13 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants (NCT07007546) | Abbisko Therapeutics Co, Ltd | 2025-05-17 |
| A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects (NCT07126249) | Abbisko Therapeutics Co, Ltd | 2025-05-13 |
| A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects (NCT06884072) | Abbisko Therapeutics Co, Ltd | 2025-04-08 |
| A Mass Balance Study of [14C]ABSK011 (NCT06896760) | Abbisko Therapeutics Co, Ltd | 2025-04-07 |
| A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects (NCT06779253) | Abbisko Therapeutics Co, Ltd | 2025-03-14 |
| A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects (NCT06694948) | Abbisko Therapeutics Co, Ltd | 2024-12-10 |
| A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib (NCT06668103) | Abbisko Therapeutics Co, Ltd | 2024-11-25 |
| A Phase 2 Clinical Study of ABSK061 and ABSK043 (NCT06632262) | Abbisko Therapeutics Co, Ltd | 2024-11-13 |
| The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function (NCT06562946) | Abbisko Therapeutics Co, Ltd | 2024-09-20 |
| A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021 (NCT06322706) | Abbisko Therapeutics Co, Ltd | 2024-03-22 |
| A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules (NCT06306872) | Abbisko Therapeutics Co, Ltd | 2024-02-23 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer (NCT06225804) | Abbisko Therapeutics Co, Ltd | 2024-02-22 |
| A Mass Balance Study of [14C]ABSK021 (NCT06186583) | Abbisko Therapeutics Co, Ltd | 2023-12-13 |
| A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer (NCT06111274) | Abbisko Therapeutics Co, Ltd | 2023-10-17 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors (NCT05627063) | Abbisko Therapeutics Co, Ltd | 2023-06-26 |
| A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) (NCT06186804) | Abbisko Therapeutics Co, Ltd | 2023-05-30 |
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) (NCT05804045) | Abbisko Therapeutics Co, Ltd | 2023-04-27 |
| A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021 (NCT06089733) | Abbisko Therapeutics Co, Ltd | 2023-04-11 |
| A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC (NCT05775874) | Abbisko Therapeutics Co, Ltd | 2022-09-30 |
| ABSK021 Food Effect Study in Healthy Subjects (NCT05280483) | Abbisko Therapeutics Co, Ltd | 2022-07-23 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors (NCT05244551) | Abbisko Therapeutics Co, Ltd | 2022-06-30 |
| A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients (NCT05441475) | Abbisko Therapeutics Co, Ltd | 2021-12-30 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor (NCT04964375) | Abbisko Therapeutics Co, Ltd | 2021-08-31 |
| A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC (NCT05103917) | Abbisko Therapeutics Co, Ltd | 2021-07-21 |
| A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 (NCT05086666) | Abbisko Therapeutics Co, Ltd | 2021-06-03 |
| ABSK091 Food Effect Study in Healthy Subjects (NCT05533788) | Abbisko Therapeutics Co, Ltd | 2020-09-08 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor (NCT04906434) | Abbisko Therapeutics Co, Ltd | 2020-02-26 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor (NCT04192344) | Abbisko Therapeutics Co, Ltd | 2020-01-20 |